Evonik makes five generations healthier with EUDRAGIT targeted drug delivery coatings

For 70 years, EUDRAGIT polymers have been used as coatings to make more effective drugs. The methacrylate polymer product portfolio has been an industry standard for decades, with more than 23,000 patents and 10,000 scientific publications mentioning the EUDRAGIT brand.

With its long experience in functional excipients, formulation and application services, Evonik offers EUDRAGIT polymers as key ingredients in multi-component systems that are tailored to unique and specific customer needs. These system solutions are driving the transformation of Evonik’s Life Sciences division Nutrition & Care, which is leveraging its expertise in biosolutions to increase its share of system solutions to 70% by 2032.

"From baby boomers to Generation Alpha, we are proud to leverage EUDRAGIT® to enable pharmaceutical innovations that improve health around the world from day one," said Thomas Riermeier, head of the Healthcare business line at Evonik.

EUDRAGIT is the industry's preferred portfolio of functional polymers for oral pharmaceuticals. EUDRAGIT's breadth, versatility and history, combined with Evonik's range of drug delivery technologies, formulations and cGMP manufacturing services, provide pharmaceutical companies with unparalleled safety, supply security and functional reliability for their oral solid dosage forms.

"Almost everyone you know come into contact with EUDRAGIT at some point in their lives," said Paul Spencer, Head of Drug Delivery and Products at Evonik. "As the population grows and ages, we look forward to continuing to innovate these polymers into next-generation solutions, such as the recently launched EUDRACAP®, which is quickly becoming the leading choice for enteric-coated capsule protection."